Beyond gout: uric acid and cardiovascular diseases

References

• Gertler M, Garn S, Levine S. Serum uric acid in relation to age and physique in health and coronary heart disease. Ann Intern Med 1951;34:1421-31
   PubMed Web of Science ®Google Scholar
• Klein R, Klein B, Cornoni J, et al. Serum uric acid: its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973;132:401-10
   PubMed Web of Science ®Google Scholar
• Alderman M, Aiyer KJ. Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-79
   PubMed Web of Science ®Google Scholar
• Dobson A. Is raised serum uric acid a cause of cardiovascular disease or death? Lancet 1999;354:1578
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Feig DI, Herrera-Acosta J, et al. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005;45:18-20
   PubMed Web of Science ®Google Scholar
• Yusuf S, Bosch J. Urate levels as a predictor of cardiac deaths: causal relation or mere association? Eur Heart J 2002;23:760-1
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072-8
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008;359:1811-21
   PubMed Web of Science ®Google Scholar
• Loeffler LF, Navas-Acien A, Brady TM, et al. Uric acid level and elevated blood pressure in US adolescents: National Health and Nutrition Examination Survey, 1999–2006. Hypertension 2012;59:811-17
   PubMed Web of Science ®Google Scholar
• Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens 2007;25:1583-9
   PubMed Web of Science ®Google Scholar
• Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9
   PubMed Web of Science ®Google Scholar
• Weir CJ, Muir SW, Walters MR, et al. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003;34:1951-7
   PubMed Web of Science ®Google Scholar
• Gerber Y, Tanne D, Medalie JH, et al. Serum uric acid and long-term mortality from stroke, coronary heart disease and all causes. Eur J Cardiovasc Prev Rehabil 2006;13:193-8
   PubMed Web of Science ®Google Scholar
• Kohagura K, Kochi M, Miyagi T, et al. An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res 2013;36:43-9
   Google Scholar
• Tamariz L, Harzand A, Palacio A, et al. Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis. Congestive Heart Failure 2011;17:25-30
   PubMedGoogle Scholar
• Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003;41:1183-90
   PubMed Web of Science ®Google Scholar
• Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005;2:e76
   PubMed Web of Science ®Google Scholar
• De Luca G, Secco GG, Santagostino M, et al; Novara Atherosclerosis Study Group (NAS). Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012;22:426-33
   PubMed Web of Science ®Google Scholar
• Wannamethee SG. Serum uric acid and risk of coronary heart disease. Curr Pharm Des 2005;11:4125-32
   PubMed Web of Science ®Google Scholar
• Amaro S, Planas AM, Chamorro A. Uric acid administration in patients with acute stroke: a novel approach to neuroprotection. Expert Rev Neurother 2008;8:259-70
   PubMedGoogle Scholar
• Baker JF, Krishnan E, Chen L, et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005;118:816-26
   PubMed Web of Science ®Google Scholar
• Strasak A, Ruttmann E, Brant L, et al. Serum uric acid and risk of cardiovascular mortality: a prospective longterm study of 83,683 Austrian men. Clin Chem 2008;54:273-84
   PubMed Web of Science ®Google Scholar
• Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104-10
   PubMed Web of Science ®Google Scholar
• Doehner W, Landmesser U. Xanthine oxidase and uric acid in cardiovascular disease: clinical impact and therapeutic options. Semin Nephrol 2011;31:433-40
   PubMed Web of Science ®Google Scholar
• Niskanen LK, Laaksonen DL, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men. Arch Intern Med 2004;164:1546-51
   PubMed Web of Science ®Google Scholar
• Gagliardi AC, Miname MH, Santos RD. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis 2009;202:11-17
   PubMed Web of Science ®Google Scholar
• Abbott RD, Brand FN, Kannel WB, et al. Gout and coronary heart disease: the Framingham study. J Clin Epidemiol 1988;41:237-42
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900
   PubMed Web of Science ®Google Scholar
• Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology 2010;49:141-6
   PubMed Web of Science ®Google Scholar
• Chen JH, Chuang SY, Chen HJ, et al. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Care Res 2009;61:225-32
   Web of Science ®Google Scholar
• Ioachimescu AG, Brennan DM, Hoar BM, et al. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum 2008;58:623-30
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971–1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-10
   PubMed Web of Science ®Google Scholar
• Bickel C, Rupprecht HJ, Blankenberg S, et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002;89:12-17
   PubMed Web of Science ®Google Scholar
• Alderman MH, Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144-50
   PubMed Web of Science ®Google Scholar
• Cherubini A, Polidori MC, Bregnocchi M, et al. Antioxidant profile and early outcome in Stroke patients. Stroke 2000;31:2295-300
   PubMed Web of Science ®Google Scholar
• Keenan RT, O’Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med 2011;124:155-63
   PubMed Web of Science ®Google Scholar
• Santos RD. Elevated uric acid, the metabolic syndrome and cardiovascular disease: cause, consequence, or just a not so innocent bystander? Endocrine 2012;41:350-2
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Dormi A, D'Addato S, Borghi C. From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study. Clinical Lipidology 2011;6:269-76
   Web of Science ®Google Scholar
• Gonçalves JP, Oliveira A, Severo M, et al. Cross-sectional and longitudinal associations between serum uric acid and metabolic syndrome. Endocrine 2012;41:450-7
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006;290:F625-31
   PubMed Web of Science ®Google Scholar
• Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003;42:474-80
   PubMed Web of Science ®Google Scholar
• Hikita M, Ohno I, Mori Y, et al. Relationship between hyperuricemia and body fat distribution. Intern Med 2007;46:1353-8
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension 1995;25(4 Pt 1):560-3
   PubMed Web of Science ®Google Scholar
• Bombelli M, Facchetti R, Fodri D et al. Impact of body mass index and waist circumference on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study. Nutr Metab Cardiovasc Dis 2012 May 25 [Epub ahead of print]
   Google Scholar
• Doehner V, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619-24
   PubMed Web of Science ®Google Scholar
• Coghlan JG, Flitter WD, Clutton SM, et al. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 1994;107:248-56
   PubMed Web of Science ®Google Scholar
• Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012;60:1148-56
   PubMed Web of Science ®Google Scholar
• Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology 2009;48:804-6
   PubMed Web of Science ®Google Scholar
• Wei L, Mackenzie IS, Chen Y, et al. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol 2011;71:600-7
   PubMed Web of Science ®Google Scholar
• Weimert NA, Tanke WF, Sims JJ. Allopurinol as a cardioprotective during coronary artery bypass graft surgery. Ann Pharmacother 2003;37:1708-11
   PubMed Web of Science ®Google Scholar
• Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-11
   PubMed Web of Science ®Google Scholar
• Chen J-H, Pan W-H. Effects of urate lowering therapy on cardiovascular mortality: a Taiwanese cohort study. Arthritis Rheum 2010;62:S872-3
   Google Scholar
• Thanassoulis G, Brophy JM, Richard H, et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170:1358-64
   PubMed Web of Science ®Google Scholar
• Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19:1814-22
   PubMed Web of Science ®Google Scholar
• Doehner W, Anker SD. Uric acid in chronic heart failure. Semin Nephrol 2005;25:61-6
   PubMed Web of Science ®Google Scholar
• Hutton CW, Collins AJ, Chambers RE, et al. Systemic response to local urate crystal induced inflammation in man: a possible model to study the acute phase response. Ann Rheum Dis 1985;44:533-6
   PubMed Web of Science ®Google Scholar
• Chen X, Li Y, Sheng CS, et al. Association of serum uric acid with aortic stiffness and pressure in a Chinese workplace setting. Am J Hypertens 2010;23:387-92
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Xaplanteris P, Vyssoulis G, et al. Association of serum uric acid level with aortic stiffness and arterial wave reflections in newly diagnosed, never-treated hypertension. Am J Hypertens 2011;24:33-9
   PubMed Web of Science ®Google Scholar
• Iwashima Y, Horio T, Kamide K, et al. Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006;47:195-202
   PubMed Web of Science ®Google Scholar
• Viazzi F, Parodi D, Leoncini G, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005;45:991-6
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Valerio C, Sala C, et al. Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. Am J Hypertens 2007;20:678-85
   PubMed Web of Science ®Google Scholar
• Patetsios P, Rodino W, Wisselink W, et al. Identification of uric acid in aortic aneurysms and atherosclerotic artery. Ann N Y Acad Sci 1996;800:243-5
   PubMed Web of Science ®Google Scholar
• Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002;51:1118-24
   PubMed Web of Science ®Google Scholar
• Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (Lond) 2004;555:589-606
   Google Scholar
• Yelken B, Caliskan Y, Gorgulu N, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol 2012;77:275-82
   PubMed Web of Science ®Google Scholar
• George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508-16
   PubMed Web of Science ®Google Scholar
• Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogenactivated protein kinase and cyclooxygenase-2. Hypertension 2003;41:1287-93
   PubMed Web of Science ®Google Scholar
• Sautin YY, Nakagawa T, Zharikov S, et al Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007;293:C584-96
   PubMed Web of Science ®Google Scholar
• Greig D, Alcaino H, Castro PF, et al. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. J Heart Lung Transplant 2011;30:408-13
   PubMed Web of Science ®Google Scholar
• Kanbay M, Afsar B, Covic A. Uric acid as a cardiometabolic risk factor: to be or not to be. Contrib Nephrol 2011;171:62-7
   PubMed Web of Science ®Google Scholar
• George J, Struthers AD. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Therapeut 2008;26:59-64
   PubMed Web of Science ®Google Scholar
• Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol 2001;38:1850-8
   PubMed Web of Science ®Google Scholar
• Farquharson CAR, Hill A, Belch JJ, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002;106:221-6
   PubMed Web of Science ®Google Scholar
• Guthikonda S, Woods K, Sinkey CA, et al. Role of xanthine oxidase in conduit artery endothelial dysfunction in cigarette smokers. Am J Cardiol 2004;93:664-8
   PubMed Web of Science ®Google Scholar
• Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing induced heart failure. Circ Res 1999;5:437-45
   Google Scholar
• Saavedra WF, Paolocci N, St. John ME, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002;90:297-304
   PubMed Web of Science ®Google Scholar
• Amado LC, Saliaris AP, Raju SV, et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing induced heart failure. J Mol Cell Cardiol 2005;39:531-6
   PubMed Web of Science ®Google Scholar
• Castro PF, Greig D, Perez O, et al. Relation between oxidative stress, catecholamines, and impaired chronotropic response to exercise in patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003;92:215-18
   PubMed Web of Science ®Google Scholar
• Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486-91
   PubMed Web of Science ®Google Scholar
• Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata study. J Card Fail 2006;12:491-8
   PubMed Web of Science ®Google Scholar
• Hare JM, Mangal B, Brown J, et al; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008;51:2301-9
   PubMed Web of Science ®Google Scholar
• Ogino K, Kato M, Furuse Y, et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail 2010;3:73-81
   PubMed Web of Science ®Google Scholar
• Harzand A, Tamariz L, Hare JM. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail 2012;18:179-82
   PubMedGoogle Scholar
• Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002;87:229-34
   PubMed Web of Science ®Google Scholar
• Kelkar A, Kuo A, Frishman WH. Allopurinol as a cardiovascular drug. Cardiol Rev 2011;19:265-71
   PubMed Web of Science ®Google Scholar
• Rajendra NS, Ireland S, George J, et al. Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol 2011;58:820-8
   PubMed Web of Science ®Google Scholar
• Kao MP, Ang DS, Gandy SJ, et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol 2011;22:1382-9
   PubMed Web of Science ®Google Scholar
• Malik UZ, Hundley NJ, Romero G, et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med 2011;51:179-84
   PubMed Web of Science ®Google Scholar
• Baldus S, Mullerleile K, Chumley P, et al. Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic Biol Med 2006;41:1282-8
   PubMed Web of Science ®Google Scholar
• Muir SW, Harrow C, Dawson J, et al. Allopurinol use yields potentially beneficial effects on inflammatory indices in those with recent ischemic stroke: a randomized, double-blind, placebo-controlled trial. Stroke 2008;39:3303-7
   PubMed Web of Science ®Google Scholar
• Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther 2012;30:217-26
   PubMed Web of Science ®Google Scholar